To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: DG DISPATCH - ADA: Troglitazone Successful As Combination Therapy For Diabetics URL: http://www.pslgroup.com/dg/109E4A.htm Doctor's Guide June 21, 1999
By Cameron Johnston Special to DG News
SAN DIEGO, CA -- June 21, 1999 -- Researchers report that troglitazone (Rezulin, Parke-Davis) has a synergistic effect when used as combination therapy with insulin in patients who do not respond to insulin.
This combination therapy not only helps patients achieve adequate glycemic control but enables those who are using insulin to reduce their daily dose too, according to the results presented at the American Diabetes Association's 59th Annual Scientific Sessions in San Diego, CA.
The researchers found that combination therapy including either 200 or 400 mg/day of troglitazone was effective in reducing levels of HbA1c and fasting plasma glucose and daily insulin requirements in type 2 diabetics whose glucose was inadequately controlled with insulin alone. These findings were presented by Dr. Lawrence Leiter, director of the lipid disorders clinic at St. Michael's Hospital, Toronto.
Among the 539 patients enrolled in the study, those whose baseline HbA1c was 140 percent above the normal range - indicating that their diabetes was not well-controlled - experienced the greatest benefit, with hemoglobins (HbA1c) levels falling by 1.35 percent from 9.55 to 8.20 percent. HbA1c levels are considered normal at 4 to 6 percent but intervention is only recommended when HbA1c exceeds 7 percent).
Fasting plasma glucose declined by 2.5 mmol/l.
Those patients whose diabetes was poorly controlled but whose HbA1c was 110 to 140 percent above normal also experienced similar reductions in the markers for insulin response. They achieved a statistically significant reduction in FPG of 1.4 mmol/l and a decline in daily insulin dose of 17.7 units. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.